Binah Capital Group, Inc.

CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced that the U.S. Food and Drug Administration (FDA) has expanded the approved indication for ANKTIVA® (nogapendekin alfa inbakicept-pmln) in combination with Bacillus Calmette-Guérin (BCG) to include patients with BCG-unresponsive NMIBC with papillary-only tumors. The expanded FDA label reads as follows: ANKTIVA, in combination with Bacillus Calmette-Guérin (BCG), is in.

Binah Capital Group, Inc. (NASDAQ: BCG - Get Free Report) was the recipient of a significant decline in short interest in September. As of September 30th, there was short interest totaling 2,413 shares, a decline of 61.0% from the September 15th total of 6,191 shares. Based on an average trading volume of 16,415 shares, the days-to-cover

Binah Capital Group (NASDAQ: BCG - Get Free Report) and Hennessy Advisors (NASDAQ: HNNA - Get Free Report) are both small-cap finance companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, profitability, earnings, analyst recommendations, valuation, institutional ownership and risk. Profitability This table compares Binah Capital

PennantPark Investment (NASDAQ: PNNT - Get Free Report) and Binah Capital Group (NASDAQ: BCG - Get Free Report) are both small-cap finance companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, dividends, analyst recommendations, profitability, risk, earnings and valuation. Earnings and Valuation This table compares

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the European Medicines Agency's Committee for Medicinal Products for Hu